Overview
Gan & Lee Pharmaceuticals, one of China’s leading insulin manufacturers, has initiated a pivotal Phase 3 clinical trial for GZR18 (also known as Bofenluride or Bofiglutide), a novel GLP-1/GIP dual agonist designed for weight management. The multicenter, randomized, double-blind, placebo-controlled study aims to enroll 630 adult participants with obesity or overweight conditions across multiple hospitals in China.
This marks a significant milestone in China’s pharmaceutical industry’s race to develop domestic alternatives to blockbuster weight-loss medications like Eli Lilly’s tirzepatide (Zepbound/Mounjaro) and Novo Nordisk’s semaglutide (Wegovy/Ozempic). The trial, which began in December 2024, represents China’s commitment to reducing dependency on imported diabetes and obesity medications.
Mechanism of Action
GZR18 is a dual agonist targeting both the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual mechanism mimics the action of natural incretin hormones, which regulate blood sugar and appetite:
- GLP-1 receptor activation: Slows gastric emptying, reduces appetite, and enhances glucose-dependent insulin secretion
- GIP receptor activation: Further amplifies insulin secretion and may improve fat metabolism
This dual-targeting approach is similar to tirzepatide, which has demonstrated superior weight loss compared to single GLP-1 agonists like semaglutide. In clinical trials, tirzepatide achieved an average weight loss of 20.9% at the highest dose (15mg), setting a high benchmark for GZR18 to match or exceed.
Phase 3 Clinical Trial Design
The Phase 3 study (NCT06728124) features a rigorous design to evaluate GZR18’s efficacy and safety:
Key Study Parameters
- Trial ID: NCT06728124
- Phase: Phase 3
- Enrollment: 630 participants
- Design: Multicenter, randomized, double-blind, parallel, placebo-controlled
- Population: Adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity
- Start Date: December 30, 2024
- Status: Active, not recruiting
Primary Endpoint
The primary outcome measure is the percentage change in body weight from baseline to the end of the treatment period. Secondary endpoints include:
- Proportion of participants achieving ≥5%, ≥10%, ≥15%, and ≥20% weight reduction
- Changes in waist circumference, BMI, and waist-to-hip ratio
- Improvements in glycemic control (HbA1c, fasting plasma glucose)
- Cardiovascular risk markers (blood pressure, lipid profile)
Phase 2 Results
Prior to the Phase 3 launch, GZR18 completed a Phase 2 study (NCT06256562) involving 340 obese or overweight participants. The 30-week trial demonstrated promising results:
- Primary endpoint: Significant percentage reduction in body weight at Week 30
- Secondary endpoints: Meaningful improvements in glycemic parameters, cardiovascular risk factors, and patient-reported quality of life scores
- Safety profile: Acceptable tolerability with side effects consistent with the GLP-1 agonist class (nausea, vomiting, diarrhea)
The successful completion of Phase 2 paved the way for the larger Phase 3 confirmatory trial, with results expected to support regulatory submission to China’s National Medical Products Administration (NMPA).
Market Impact and Competition
The development of GZR18 comes at a critical time for China’s pharmaceutical market:
Global Weight-Loss Drug Market
- The global anti-obesity medication market is projected to reach $100 billion by 2030
- Tirzepatide (Eli Lilly) and semaglutide (Novo Nordisk) dominate the market
- Supply shortages have limited access in many countries, including China
China’s Position
- China has over 180 million adults with obesity, creating enormous demand
- Imported GLP-1 medications are expensive and often unavailable due to supply constraints
- Domestic development of GZR18 could provide affordable alternatives for Chinese patients
- Gan & Lee’s expertise in insulin production positions the company well for large-scale peptide manufacturing
Competitive Landscape
Several Chinese pharmaceutical companies are racing to develop GLP-1 based weight-loss drugs:
- Gan & Lee Pharmaceuticals (GZR18): Phase 3, dual GLP-1/GIP agonist
- Huadong Medicine (HDM1005): Phase 2, directly comparing against tirzepatide
- Lotus Pharmaceutical: Multiple GLP-1 candidates in development
Participating Hospitals
The Phase 3 trial is being conducted across multiple leading hospitals in China, including facilities in Beijing and other major cities. These hospitals have extensive experience in endocrinology and metabolic disease research:
- Leading tertiary hospitals in Beijing
- Specialized endocrinology centers with expertise in diabetes and obesity management
- Hospitals with clinical trial capabilities meeting international standards
For international patients interested in accessing GZR18 or similar treatments, these participating hospitals represent potential destinations for medical tourism once the drug receives regulatory approval.
Future Outlook
The development of GZR18 represents a strategic shift in China’s pharmaceutical industry:
Regulatory Timeline
- Phase 3 results expected: 2026-2027
- Potential NMPA approval: 2027-2028
- International expansion: Possible FDA submission if Phase 3 data is positive
Global Implications
- Could alleviate global supply constraints for GLP-1 medications
- May offer cost-effective alternatives for patients worldwide
- Positions China as a major player in the metabolic disease therapeutic area
Medical Tourism Potential
Once approved, GZR18 could attract international patients seeking affordable weight-loss treatments. China’s medical tourism sector is rapidly developing, with hospitals offering:
- English-speaking medical staff
- International patient services
- Competitive pricing compared to Western countries
- Access to cutting-edge treatments not yet available elsewhere